These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 32294244)

  • 1. Periodontal regeneration by leukocyte and platelet-rich fibrin with autogenous bone graft versus enamel matrix derivative with autogenous bone graft in the treatment of periodontal intrabony defects: A randomized non-inferiority trial.
    Paolantonio M; Di Tullio M; Giraudi M; Romano L; Secondi L; Paolantonio G; Graziani F; Pilloni A; De Ninis P; Femminella B
    J Periodontol; 2020 Dec; 91(12):1595-1608. PubMed ID: 32294244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Unfavorable Intrabony Defects with Autogenous Bone Graft in Combination with Leukocyte- and Platelet-Rich Fibrin or Collagen Membranes: A Non-Inferiority Study.
    Balice G; Paolantonio M; De Ninis P; Rexhepi I; Serroni M; Frisone A; Romano L; Sinjari B; Murmura G; Femminella B
    Medicina (Kaunas); 2024 Jul; 60(7):. PubMed ID: 39064520
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of inorganic bovine bone combined with leukocyte and platelet-rich fibrin or collagen membranes for treating unfavorable periodontal infrabony defects: Randomized non-inferiority trial.
    Rexhepi I; Paolantonio M; Romano L; Serroni M; Santamaria P; Secondi L; Paolantonio G; Sinjari B; De Ninis P; Femminella B
    J Periodontol; 2021 Nov; 92(11):1576-1587. PubMed ID: 33547808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial.
    Csifó-Nagy BK; Sólyom E; Bognár VL; Nevelits A; Dőri F
    BMC Oral Health; 2021 Nov; 21(1):580. PubMed ID: 34781955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of intrabony defects using guided tissue regeneration or enamel matrix derivative: a 3-year prospective randomized clinical study.
    Crea A; Dassatti L; Hoffmann O; Zafiropoulos GG; Deli G
    J Periodontol; 2008 Dec; 79(12):2281-9. PubMed ID: 19053918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration. A prospective controlled clinical study.
    Sculean A; Windisch P; Chiantella GC; Donos N; Brecx M; Reich E
    J Clin Periodontol; 2001 May; 28(5):397-403. PubMed ID: 11350501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of platelet-rich fibrin vs. enamel matrix derivative in the treatment of periodontal intrabony defects: a clinical and cone beam computed tomography study.
    Gupta SJ; Jhingran R; Gupta V; Bains VK; Madan R; Rizvi I
    J Int Acad Periodontol; 2014 Jul; 16(3):86-96. PubMed ID: 25654961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of platelet-rich fibrin and autogenous bone graft for the treatment of infrabony defects in chronic periodontitis: Clinical, radiological, and surgical reentry.
    Galav S; Chandrashekar KT; Mishra R; Tripathi V; Agarwal R; Galav A
    Indian J Dent Res; 2016; 27(5):502-507. PubMed ID: 27966508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year results evaluating the effects of platelet-rich plasma on the healing of intrabony defects treated with enamel matrix derivative and natural bone mineral.
    Döri F; Arweiler N; Húszár T; Gera I; Miron RJ; Sculean A
    J Periodontol; 2013 Nov; 84(11):1546-55. PubMed ID: 23327604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enamel matrix derivative (Emdogain) for periodontal tissue regeneration in intrabony defects. A Cochrane systematic review.
    Esposito M; Grusovin MG; Papanikolaou N; Coulthard P; Worthington HV
    Eur J Oral Implantol; 2009; 2(4):247-66. PubMed ID: 20467602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes after treatment of non-contained intrabony defects with enamel matrix derivative or guided tissue regeneration: a 12-month randomized controlled clinical trial.
    Siciliano VI; Andreuccetti G; Siciliano AI; Blasi A; Sculean A; Salvi GE
    J Periodontol; 2011 Jan; 82(1):62-71. PubMed ID: 20809859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apical approach in periodontal reconstructive surgery with enamel matrix derivate and enamel matrix derivate plus bone substitutes: a randomized, controlled clinical trial.
    Moreno Rodríguez JA; Ortiz Ruiz AJ
    Clin Oral Investig; 2022 Mar; 26(3):2793-2805. PubMed ID: 34791548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsurgical access flap and enamel matrix derivative for the treatment of periodontal intrabony defects: a controlled clinical study.
    Wachtel H; Schenk G; Böhm S; Weng D; Zuhr O; Hürzeler MB
    J Clin Periodontol; 2003 Jun; 30(6):496-504. PubMed ID: 12795787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-year results following treatment of intrabony periodontal defects with an enamel matrix derivative alone or combined with a biphasic calcium phosphate.
    Pietruska M; Pietruski J; Nagy K; Brecx M; Arweiler NB; Sculean A
    Clin Oral Investig; 2012 Aug; 16(4):1191-7. PubMed ID: 21881869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Added benefit of L-PRF to autogenous bone grafts in the treatment of degree II furcation involvement in mandibular molars.
    Serroni M; Paolantonio M; Romano L; Santamaria P; Rexhepi I; Sinjari B; Paolantonio G; Secondi L; De Ninis P; Femminella B
    J Periodontol; 2022 Oct; 93(10):1486-1499. PubMed ID: 34910825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of surgical flap design (minimally invasive flap vs. extended flap with papilla preservation) on the healing of intrabony defects treated with an enamel matrix derivative: a 12-month two-center randomized controlled clinical trial.
    Windisch P; Iorio-Siciliano V; Palkovics D; Ramaglia L; Blasi A; Sculean A
    Clin Oral Investig; 2022 Feb; 26(2):1811-1821. PubMed ID: 34491446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of intrabony periodontal defects in controlled diabetic patients with an enamel matrix derivative: a split-mouth randomized clinical trial.
    Cimões R; Santiago LM; de França Caldas Júnior A; de Carvalho Farias Vajgel B; Perussolo J; Donos N
    Clin Oral Investig; 2022 Mar; 26(3):2479-2489. PubMed ID: 34643808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the adjunctive effect of platelet-rich fibrin to enamel matrix derivative in the treatment of intrabony defects. Six-month results of a randomized, split-mouth, controlled clinical study.
    Aydemir Turkal H; Demirer S; Dolgun A; Keceli HG
    J Clin Periodontol; 2016 Nov; 43(11):955-964. PubMed ID: 27396428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical, radiographic, and histometric measurements following treatment with guided tissue regeneration or enamel matrix proteins in human periodontal defects.
    Windisch P; Sculean A; Klein F; Tóth V; Gera I; Reich E; Eickholz P
    J Periodontol; 2002 Apr; 73(4):409-17. PubMed ID: 11990442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healing of two and three wall intrabony periodontal defects following treatment with an enamel matrix derivative combined with autogenous bone.
    Yilmaz S; Cakar G; Yildirim B; Sculean A
    J Clin Periodontol; 2010 Jun; 37(6):544-50. PubMed ID: 20507378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.